logobeta
본 영문본은 리걸엔진의 AI 번역 엔진으로 번역되었습니다. 수정이 필요한 부분이 있는 경우 피드백 부탁드립니다.
텍스트 조절
arrow
arrow
(영문) 전주지방법원군산지원 2015.01.08 2013가단52665
손해배상(의)
Text

1. The plaintiff's claim is dismissed.

2. The costs of lawsuit shall be borne by the Plaintiff.

Reasons

1. Basic facts

A. The next hospital of the Defendant medical corporation’s artificial medical foundation (hereinafter “Defendant corporation”) is a medical corporation that operates the next hospital located in the Gunsan City (hereinafter “Defendant hospital”), and the Plaintiff at the Defendant hospital:

A person who has undergone an operation like paragraph, and the defendant B works in the defendant hospital and performed the plaintiff.

B. The progress of the medical treatment and operation of the Plaintiff at the Defendant Hospital is as follows.

1) Around May 14, 2011, the Plaintiff felled into the Defendant Hospital and went to the Defendant Hospital. Around May 14, 2011, the Defendant Hospital was diagnosed with the escape certificate of the scopical scopical scopical scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopic scopics.

3) After the Plaintiff’s discharge, the Plaintiff re-hospitalized the Defendant Hospital again on May 25, 201. The Defendant Hospital confirmed that the Plaintiff’s self-official film and blood test was conducted with respect to the Plaintiff, that the C-C-C-C-C-C-C-react protein and CRP was high, and then invested two times a day in 1g of the Macamomic acid (1g of the Macam) with respect to salt, and that the CRP value decreased after the Plaintiff was administered with the Macamic acid (4). From June 4, 2011, the Defendant Hospital began to administer the Macamicide to the Plaintiff as a light.

However, around June 13, 2011, the plaintiff's CRP value has risen again, and the defendant hospital conducted a flive test at the upper part of the plaintiff's operation, and then replaced the two-generation third-generation third-generation third-generation third-generation third-generation third-generation third-generation third-generation third-generation third-generation third-generation navigation product.

arrow